

# IgE receptor antagonists - Pipeline Insight, 2022

<https://marketpublishers.com/r/I7C601037244EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: I7C601037244EN

## Abstracts

This report can be delivered to the clients within 2-3 Business Days

DelveInsight's, "IgE receptor antagonists - Pipeline Insight, 2022" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in IgE receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### IgE receptor antagonists Understanding

#### IgE receptor antagonists: Overview

Immunoglobulin E is responsible for the pathogenesis of many allergic diseases including asthma. The primary role of IgE is defense against parasitic disease such as helminthes and protozoa. IgE, like all immunoglobulins, is composed of two light chains and two identical heavy chains. The heavy chain for IgE is epsilon. IgE is a monomer and consists of four constant regions. The constant region, C-epsilon-3, binds to both the low- and high-affinity IgE receptor. Omalizumab is a recombinant humanized monoclonal antibody that binds IgE and has been used treat allergic asthma for over a decade. Currently, omalizumab is approved for the treatment of both allergic asthma and chronic spontaneous urticaria. Since IgE plays a critical role in other allergic diseases, anti-IgE therapy has been evaluated in other allergic diseases in small clinical

trials and case reports. Omalizumab has demonstrated efficacy in treating allergic rhinitis, atopic dermatitis, physical urticarias, mast cell disorders, food allergy, and other allergic diseases. In addition, the use of omalizumab with conventional allergen immunotherapy improves both safety and effectiveness.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence IgE receptor antagonists R&D. The therapies under development are focused on novel approaches for IgE receptor antagonists.

## IgE receptor antagonists Emerging Drugs Chapters

This segment of the IgE receptor antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## IgE receptor antagonists Emerging Drugs

### Genolair (Omalizumab biosimilar): Generium Pharmaceuticals

Omalizumab is a humanised monoclonal antibody produced using recombinant DNA that selectively binds to immunoglobulin (IgE). Omalizumab binds to IgE and blocks its interaction with a high affinity Fc $\gamma$ RI receptor. Thus, there is a decrease in the amount of free IgE, which is a triggering factor for the cascade of allergic reactions. Omalizumab is the only class of biological anti-IgE therapy recommended for the treatment of atopic bronchial asthma; it helps withdraw or reduce the intake of glucocorticosteroids and also reduces the number and incidence of exacerbations.

### Omalizumab (Xolair): Zhimeng Biopharma

Omalizumab is a monoclonal anti-immunoglobulin E antibody used in the treatment of severe asthma and chronic idiopathic urticaria. Omalizumab, manufactured by

Genentech, was first FDA approved in 2003 to treat adults and children 12 years of age and older with moderate to severe persistent allergic asthma which is not controlled by inhaled steroids. Since its U.S. approval, more than 200,000 patients older than 12 with allergic asthma have been treated. In September 2018, a new prefilled syringe formulation of this drug was approved by the FDA. Currently, it is in Phase III stage of clinical trial evaluation to treat Peanut hypersensitivity.

Further product details are provided in the report.....

### IgE receptor antagonists: Therapeutic Assessment

This segment of the report provides insights about the different IgE receptor antagonists drugs segregated based on following parameters that define the scope of the report, such as:

#### Major Players working on IgE receptor antagonists

There are approx. 12+ key companies which are developing the IgE receptor antagonists. The companies which have their IgE receptor antagonists drug candidates in the most advanced stage, i.e. Phase III include, Generium Pharmaceuticals.

#### Phases

DelveInsight's report covers around 12+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

IgE receptor antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

## Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

## IgE receptor antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses IgE receptor antagonists therapeutic drugs key players involved in developing key drugs.

## Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging IgE receptor antagonists drugs.

## IgE receptor antagonists Report Insights

IgE receptor antagonists Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

## IgE receptor antagonists Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

## Unmet Needs

### Key Questions

#### Current Scenario and Emerging Therapies:

How many companies are developing IgE receptor antagonists drugs?

How many IgE receptor antagonists drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of IgE receptor antagonists?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the IgE receptor antagonists therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for IgE receptor antagonists and their status?

What are the key designations that have been granted to the emerging drugs?

### Key Players

Generium Pharmaceuticals

Genentech

Celltrion

Glenmark Pharmaceuticals Ltd

Helixmith

United BioPharma

Biosana

PharmAbcine

Hisun BioRay

Aimmune Therapeutics

Synermore Biologics

Shanghai Biomabs Pharmaceuticals

Eden Biologics

#### Key Products

Genolair

Omalizumab

CT-P 39

GBR 310

PG 102

BP-001

UB 221

PMC 904

HS-632

AIMab 7195

SYN-008

CMAB-007



## Contents

Introduction

Executive Summary

IgE receptor antagonists: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

IgE receptor antagonists – DelveInsight's Analytical Perspective

Late Stage Products (Phase III)

Comparative Analysis

Genolair: Generium Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

PG 102: Helixmith

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

UB 221: United BioPharma

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis  
HS-632: Hisun BioRay  
Product Description  
Research and Development  
Product Development Activities  
Drug profiles in the detailed report.....  
Inactive Products  
Comparative Analysis  
IgE receptor antagonists Key Companies  
IgE receptor antagonists Key Products  
IgE receptor antagonists- Unmet Needs  
IgE receptor antagonists- Market Drivers and Barriers  
IgE receptor antagonists- Future Perspectives and Conclusion  
IgE receptor antagonists Analyst Views  
IgE receptor antagonists Key Companies  
Appendix

## I would like to order

Product name: IgE receptor antagonists - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/I7C601037244EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I7C601037244EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970